土三七导致肝窦阻塞综合征伴门静脉血栓形成1例报道与文献复习

doi:10.3969/j.issn.1672-5069.2025.06.039

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (6): 954-956.doi: 10.3969/j.issn.1672-5069.2025.06.039

土三七导致肝窦阻塞综合征伴门静脉血栓形成1例报道与文献复习

梁胜凯, 尹晓春, 张峰, 诸葛宇征

210008 南京市南京大学医学院附属鼓楼医院消化科

收稿日期:2025-06-16 出版日期:2025-11-10 发布日期:2025-11-13
通讯作者: 诸葛宇征,E-mail:yuzheng9111963@aliyun.com
作者简介:梁胜凯,男,30岁,博士研究生。E-mail:kaii6668@163.com

Hepatic sinusoidal obstruction syndrome induced by gynura segetum with portal vein thrombosis: A case report and literature review

Liang Shengkai, Yin Xiaochun, Zhang Feng, et al

Department of Gastroenterology, Drum Tower Hospital, Affiliated to Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China

Received:2025-06-16 Online:2025-11-10 Published:2025-11-13

摘要/Abstract

关键词: 肝窦阻塞综合征, 吡咯烷生物碱, 门静脉血栓形成, 病例报道

Abstract: We reported a case of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome (PA-HSOS) complicated by portal vein thrombosis (PVT) here, and successfully dealt with transjugular intrahepatic portosystemic shunt (TIPS). The patient had a clear history of ingesting PA-containing herbal medicine (Gynura segetum, commonly known as Tusanqi). Initial anticoagulation therapy proved ineffective, but significant symptomatic improvement was observed following TIPS intervention. This report includes a literature review with an overview and analysis of the pathophysiology, clinical features, diagnostic strategies, and therapeutic options for HSOS complicated by PVT, aiming to enhance clinicians’ understanding and management of this rare but serious entity.

Key words: Hepatic sinusoidal obstruction syndrome, Pyrrolidine alkaloid, Portal vein thrombosis, Case report

梁胜凯, 尹晓春, 张峰, 诸葛宇征. 土三七导致肝窦阻塞综合征伴门静脉血栓形成1例报道与文献复习[J]. 实用肝脏病杂志, 2025, 28(6): 954-956.

Liang Shengkai, Yin Xiaochun, Zhang Feng, et al. Hepatic sinusoidal obstruction syndrome induced by gynura segetum with portal vein thrombosis: A case report and literature review[J]. Journal of Practical Hepatology, 2025, 28(6): 954-956.

参考文献

[1] Elkrief L, Hernandez-Gea V, Senzolo M, et al. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies. Lancet Gastroenterol Hepatol, 2024, 9(9): 859-883.
[2] Bagot C N, Arya R. Virchow and his triad: a question of attribution. Bri J Haematol, 2008, 143(2): 180-190.
[3] Ogren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol, 2006, 12(13): 2115-2119.
[4] 赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展. 实用肝脏病杂志, 2021, 24(5): 613-616.
[5] Edgar J A, Molyneux R J, Colegate S M. Pyrrolizidine alkaloids: Potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol, 2015, 28(1): 4-20.
[6] Xu J, Wang W, Yang X, et al. Pyrrolizidine alkaloids: An update on their metabolism and hepatotoxicity mechanism. Liver Res, 2019, 3(3): 176-184.
[7] Garcia-Tsao G, Abraldes J G, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md.), 2017, 65(1): 310-335.
[8] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海). 中华消化杂志, 2020, 40(11): 721-730.
[9] Garcia-Pagán J C, Valla D C. Primary Budd-Chiari syndrome. New Engl J Med, 2023, 388(14): 1307-1316.
[10] Tong Y, Zhang M, Qi Z, et al. Hepatic venous occlusion type of Budd-Chiari syndrome versus pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: A multi-center retrospective study. J Personal Med, 2023, 13(4): 603.
[11] Zhuge Y, Liu Y, Xie W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatoly, 2019, 34(4): 634-642.
[12] 张明. 肝硬化门静脉血栓形成诊治新进展. 实用肝脏病杂志, 2024, 27(1): 11-15.
[13] Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and Meta-analysis. Gastroenterology, 2017, 153(2): 480-487,e1.
[14] Lyu Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut, 2018, 67(12): 2156-2168.
[15] Lyu Y, Bai W, Li K, et al. Anticoagulation and transjugular intrahepatic oortosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study. Am J Gastroenterol, 2021, 116(7): 1447-1464.
[16] Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol, 2011, 54(1): 78-88.
[17] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 临床肝胆病杂志, 2017, 33(9): 1627-1637.
[18] Wang X, Zhang W, Zhang M, et al. Development of a drum tower severity scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int, 2022, 16(3): 669-679.
[19] Wu F, Yu J, Gan H, et al. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Sci Rep, 2021, 11(1): 21743.

土三七导致肝窦阻塞综合征伴门静脉血栓形成1例报道与文献复习

Hepatic sinusoidal obstruction syndrome induced by gynura segetum with portal vein thrombosis: A case report and literature review

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

[1]	姚羽, 宁波. 肝硬化门静脉血栓形成机制、自发性再通和抗凝治疗研究进展^*[J]. 实用肝脏病杂志, 2025, 28(6): 801-804.
[2]	陆涛, 李家国, 李士伟, 姚豪杰. 脾切除术联合门奇静脉断流术治疗乙型肝炎肝硬化患者门静脉血栓形成影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(6): 882-885.
[3]	汪闯, 周林, 高焕焕, 陈敬锋, 王彬阶. 脾切除术后乙型肝炎肝硬化患者血栓弹力图参数和凝血功能指标预测门静脉血栓形成的价值研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 739-742.
[4]	丁雯瑾, 范建高, 曾静. 1例复杂肝损害患者诊断经验介绍[J]. 实用肝脏病杂志, 2025, 28(5): 792-793.
[5]	周丽丽, 施漪雯, 范建高, 孙超. 伴有ABCA1基因突变的青年代谢相关脂肪性肝硬化1例报道[J]. 实用肝脏病杂志, 2024, 27(4): 638-640.
[6]	吴大海, 刘其林, 卢杰夫, 梁玉梅. 乙型肝炎肝硬化并发门静脉血栓形成患者中性粒细胞胞外陷阱标志物变化^*[J]. 实用肝脏病杂志, 2024, 27(3): 394-397.
[7]	靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 3-6.
[8]	张明. 肝硬化门静脉血栓形成诊治新进展[J]. 实用肝脏病杂志, 2024, 27(1): 11-15.
[9]	石翠翠, 徐正婕, 周惠清, 范建高. JAK2V617F基因突变阳性骨髓增殖性肿瘤相关门静脉海绵样变性1例[J]. 实用肝脏病杂志, 2023, 26(3): 443-444.
[10]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[11]	诸葛宇征, 王烜. 吡咯生物碱相关肝窦阻塞综合征研究进展^*[J]. 实用肝脏病杂志, 2021, 24(5): 617-620.
[12]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.
[13]	肖江强, 张明. 肝静脉压力梯度联合脾动脉造影诊断左侧门脉高压1例^*[J]. 实用肝脏病杂志, 2018, 21(5): 811-812.
[14]	张骏飞综述, 刘波, 陈从新审校. 含吡咯烷生物碱的中草药致肝窦阻塞综合征研究进展[J]. 实用肝脏病杂志, 2014, 17(4): 445-455.